肝细胞癌免疫检查点抑制剂毒性的诊断与管理
本综述聚焦肝细胞癌(HCC)患者接受免疫检查点抑制剂(ICI)治疗时的毒性管理。HCC多发生于肝硬化背景,肝外器官功能障碍可与免疫相关不良事件(irAE)表现重叠,增加诊断与管理难度。现有irAE指南未专门考虑肝癌与肝硬化情境,文中提供了肝性irAE管理的具体算法。
要点
- HCC患者irAE总体发生率与其他瘤种相近,但肝性irAE有升高趋势。
- 肝硬化所致肝外器官功能障碍可与irAE表现重叠或加重其严重程度。
- 现有irAE指南未专门考虑肝癌与肝硬化患者,需专门评估流程。
核心结论
- HCC患者的ICI毒性管理需结合 underlying 肝硬化背景,现有通用irAE指南未专门覆盖该人群。
- 文中提供了针对肝性irAE的具体管理算法。
研究设计与样本
- 综述,聚焦HCC患者ICI治疗的毒性谱及肝硬化对诊断与管理的挑战。
主要发现
- irAE可累及几乎全部器官,主要影响皮肤、消化系统、肺、内分泌腺、神经系统、肾、血细胞及肌肉骨骼系统。
- irAE通常可控但可危及生命。
- HCC患者irAE发生率与其他瘤种差异不大,但肝性irAE有升高趋势。
- 肝硬化肝外器官功能障碍可与irAE表现重叠或增加其严重程度。
- 挑战包括识别延迟、检查不充分、治疗延迟、过度诊断与不恰当中断ICI、免疫抑制治疗并发症及费用增加。
临床怎么用
- 在HCC合并肝硬化患者中评估毒性时需考虑肝硬化系统表现与irAE的重叠。
- 避免过度诊断导致不恰当中断ICI治疗。
- 关注免疫抑制治疗在肝硬化患者中的并发症风险。
- 可参照文中提供的肝性irAE管理算法进行管理。
局限性
- 现有irAE指南未专门考虑肝癌与肝硬化患者的毒性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors (ICIs) have reshaped cancer therapy. ICIs enhance T cell activation through various mechanisms and may help reverse the exhausted phenotype of tumour-infiltrating lymphocytes. However, disrupting the key role that checkpoint molecules play in immune homeostasis may result in autoimmune complications. A broad range of immune-related adverse events (irAEs) involve almost every organ but mostly affect the skin, digestive system, lung, endocrine glands, nervous system, kidney, blood cells, and musculoskeletal system. They are usually manageable but can be life-threatening. The incidence of irAEs is not very different in patients with hepatocellular carcinoma (HCC) compared to other tumour types, although there is a trend towards a higher incidence of hepatic irAEs. HCC usually develops on a background of cirrhosis with associated systemic manifestations. Extrahepatic organ dysfunction in cirrhosis may cause signs and symptoms that overlap with irAEs or increase their severity. Available guidelines for the management of irAEs have not specifically considered the assessment of toxicities in the context of patients with liver cancer and cirrhosis. This review addresses the toxicity profile of ICIs in patients with HCC, focusing on the challenges that the underlying liver disease poses to their diagnosis and management. Challenges include late recognition, inadequate work-up and delayed treatment, overdiagnosis and inappropriate interruption of ICIs, complications caused by immunosuppressive therapy, and increased cost. A specific algorithm for the management of hepatic irAEs is provided.
引用
- Sangro B, Chan SL, Meyer T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020. PMID: 31954495. doi:10.1016/j.jhep.2019.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。